The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Am J Public Health. 2010 Apr 1;100 Suppl 1(Suppl 1):S105-12. doi: 10.2105/AJPH.2009.162982. Epub 2010 Feb 10.
Older adults are vastly underrepresented in clinical trials in spite of shouldering a disproportionate burden of disease and consumption of prescription drugs and therapies, restricting treatments' generalizability, efficacy, and safety. Eliminating Disparities in Clinical Trials, a national initiative comprising a stakeholder network of researchers, community advocates, policymakers, and federal representatives, undertook a critical analysis of older adults' structural barriers to clinical trial participation. We present practice and policy change recommendations emerging from this process and their rationale, which spanned multiple themes: (1) decision making with cognitively impaired patients; (2) pharmacokinetic differences and physiological age; (3) health literacy, communication, and aging; (4) geriatric training; (5) federal monitoring and accountability; (6) clinical trial costs; and (7) cumulative effects of aging and ethnicity.
尽管老年人在疾病负担和处方药及治疗方法的使用方面不成比例,但他们在临床试验中却严重缺乏代表性,这限制了治疗方法的普遍性、疗效和安全性。由研究人员、社区倡导者、政策制定者和联邦代表组成的利益相关者网络发起了一项名为“消除临床试验中的差异”的国家倡议,对老年人参与临床试验的结构性障碍进行了批判性分析。我们提出了这一过程中出现的实践和政策变革建议及其基本原理,这些建议涵盖了多个主题:(1)与认知障碍患者一起做出决策;(2)药代动力学差异和生理年龄;(3)健康素养、沟通和老龄化;(4)老年医学培训;(5)联邦监督和问责制;(6)临床试验成本;以及(7)衰老和种族的累积效应。